[Form 3] ProMIS Neurosciences Inc. Initial Statement of Beneficial Ownership
ProMIS Neurosciences (PMN) Form 3: The filing shows initial beneficial ownership by Shaf QIC LLC and Shafmaster Jonathan, each identified as a director and 10% owner. The report discloses 5,184,760 common shares held directly and three classes of warrants exercisable into common shares: 100,000 shares at $7.50 (exercisable 04/11/2028), 1,063,830 shares at $1.75 (exercisable 02/23/2029), and 4,186,049 shares at $1.25 (exercisable 07/29/2030). Some warrants include a 9.99% ownership exercise limitation.
ProMIS Neurosciences (PMN) Form 3: La dichiarazione indica la proprietà iniziale da parte di Shaf QIC LLC e Shafmaster Jonathan, ciascuno identificato come amministratore e proprietario del 10%. Il rapporto rivela il possesso diretto di 5.184.760 azioni ordinarie e tre tipologie di warrant convertibili in azioni ordinarie: 100.000 azioni a $7,50 (esercitabili il 11/04/2028), 1.063.830 azioni a $1,75 (esercitabili il 23/02/2029) e 4.186.049 azioni a $1,25 (esercitabili il 29/07/2030). Alcuni warrant prevedono un limite di esercizio pari al 9,99% della proprietà.
ProMIS Neurosciences (PMN) Form 3: La presentación muestra la propiedad inicial por parte de Shaf QIC LLC y Shafmaster Jonathan, cada uno identificado como director y propietario del 10%. El informe revela la tenencia directa de 5.184.760 acciones ordinarias y tres clases de warrants ejercitables en acciones ordinarias: 100.000 acciones a $7,50 (ejercitables el 11/04/2028), 1.063.830 acciones a $1,75 (ejercitables el 23/02/2029) y 4.186.049 acciones a $1,25 (ejercitables el 29/07/2030). Algunos warrants incluyen una limitación de ejercicio del 9,99% de propiedad.
ProMIS Neurosciences (PMN) Form 3: 제출서류는 Shaf QIC LLC와 Shafmaster Jonathan의 초기 유익 소유를 보여주며, 각각 이사이자 10% 소유자로 기재되어 있습니다. 보고서는 5,184,760주의 보통주 직접 보유와 보통주로 전환 가능한 세 종류의 워런트를 공개합니다: 100,000주는 $7.50 (2028-04-11 행사 가능), 1,063,830주는 $1.75 (2029-02-23 행사 가능), 4,186,049주는 $1.25 (2030-07-29 행사 가능). 일부 워런트에는 9.99% 소유 제한이 포함되어 있습니다.
ProMIS Neurosciences (PMN) Form 3 : Le dépôt révèle une propriété initiale bénéficiaire par Shaf QIC LLC et Shafmaster Jonathan, chacun identifié comme administrateur et détenteur de 10 %. Le rapport indique la détention directe de 5 184 760 actions ordinaires et trois catégories de warrants convertibles en actions : 100 000 actions à 7,50 $ (exerçables le 11/04/2028), 1 063 830 actions à 1,75 $ (exerçables le 23/02/2029) et 4 186 049 actions à 1,25 $ (exerçables le 29/07/2030). Certains warrants comportent une limitation d'exercice à 9,99 % de participation.
ProMIS Neurosciences (PMN) Form 3: Die Einreichung weist eine anfängliche wirtschaftliche Eigentümerschaft durch Shaf QIC LLC und Shafmaster Jonathan aus, die jeweils als Direktor und 10%-Eigentümer genannt sind. Der Bericht gibt 5.184.760 Stammaktien im direkten Besitz sowie drei Arten von Wandelrechten in Stammaktien an: 100.000 Aktien zu $7,50 (ausübbar am 11.04.2028), 1.063.830 Aktien zu $1,75 (ausübbar am 23.02.2029) und 4.186.049 Aktien zu $1,25 (ausübbar am 29.07.2030). Einige Warrants enthalten eine Ausübungsbeschränkung von 9,99% des Eigentums.
- Clear disclosure of direct ownership: 5,184,760 common shares reported
- Detailed warrant information including exercisable dates, expiration dates, and exercise prices
- Exercise limitation disclosed (warrants contain a 9.99% ownership exercise cap)
- Large insider stake is disclosed (5,184,760 shares plus warrants convertible into 5,349,879 shares), which could concentrate ownership
- Potential dilution from warrants exercisable into a significant number of shares (total underlying reported warrants: 5,349,879)
Insights
TL;DR: Routine initial insider disclosure showing significant direct holdings and multiple exercisable warrants.
The Form 3 documents that Shaf QIC LLC and Shafmaster Jonathan are directors and report direct ownership of 5,184,760 common shares plus warrants convertible into a total of 5,349,879 additional shares across three tranches with exercise prices of $7.50, $1.75, and $1.25. The presence of a 9.99% exercise cap on certain warrants is explicitly disclosed. This is a standard Section 16 initial filing and provides transparency on potential dilution and insider stake size.
TL;DR: Disclosure identifies insiders with a large beneficial stake and warrants that could materially increase ownership if exercised.
The filing confirms director status and beneficial ownership levels for the reporting persons. It lists direct common shares and warrants with specific exercisable dates and prices, plus an explicit anti-exercise provision limiting aggregate ownership to 9.99% for certain warrants. This provides clear information for assessing insider influence and potential future voting/dilution scenarios.
ProMIS Neurosciences (PMN) Form 3: La dichiarazione indica la proprietà iniziale da parte di Shaf QIC LLC e Shafmaster Jonathan, ciascuno identificato come amministratore e proprietario del 10%. Il rapporto rivela il possesso diretto di 5.184.760 azioni ordinarie e tre tipologie di warrant convertibili in azioni ordinarie: 100.000 azioni a $7,50 (esercitabili il 11/04/2028), 1.063.830 azioni a $1,75 (esercitabili il 23/02/2029) e 4.186.049 azioni a $1,25 (esercitabili il 29/07/2030). Alcuni warrant prevedono un limite di esercizio pari al 9,99% della proprietà.
ProMIS Neurosciences (PMN) Form 3: La presentación muestra la propiedad inicial por parte de Shaf QIC LLC y Shafmaster Jonathan, cada uno identificado como director y propietario del 10%. El informe revela la tenencia directa de 5.184.760 acciones ordinarias y tres clases de warrants ejercitables en acciones ordinarias: 100.000 acciones a $7,50 (ejercitables el 11/04/2028), 1.063.830 acciones a $1,75 (ejercitables el 23/02/2029) y 4.186.049 acciones a $1,25 (ejercitables el 29/07/2030). Algunos warrants incluyen una limitación de ejercicio del 9,99% de propiedad.
ProMIS Neurosciences (PMN) Form 3: 제출서류는 Shaf QIC LLC와 Shafmaster Jonathan의 초기 유익 소유를 보여주며, 각각 이사이자 10% 소유자로 기재되어 있습니다. 보고서는 5,184,760주의 보통주 직접 보유와 보통주로 전환 가능한 세 종류의 워런트를 공개합니다: 100,000주는 $7.50 (2028-04-11 행사 가능), 1,063,830주는 $1.75 (2029-02-23 행사 가능), 4,186,049주는 $1.25 (2030-07-29 행사 가능). 일부 워런트에는 9.99% 소유 제한이 포함되어 있습니다.
ProMIS Neurosciences (PMN) Form 3 : Le dépôt révèle une propriété initiale bénéficiaire par Shaf QIC LLC et Shafmaster Jonathan, chacun identifié comme administrateur et détenteur de 10 %. Le rapport indique la détention directe de 5 184 760 actions ordinaires et trois catégories de warrants convertibles en actions : 100 000 actions à 7,50 $ (exerçables le 11/04/2028), 1 063 830 actions à 1,75 $ (exerçables le 23/02/2029) et 4 186 049 actions à 1,25 $ (exerçables le 29/07/2030). Certains warrants comportent une limitation d'exercice à 9,99 % de participation.
ProMIS Neurosciences (PMN) Form 3: Die Einreichung weist eine anfängliche wirtschaftliche Eigentümerschaft durch Shaf QIC LLC und Shafmaster Jonathan aus, die jeweils als Direktor und 10%-Eigentümer genannt sind. Der Bericht gibt 5.184.760 Stammaktien im direkten Besitz sowie drei Arten von Wandelrechten in Stammaktien an: 100.000 Aktien zu $7,50 (ausübbar am 11.04.2028), 1.063.830 Aktien zu $1,75 (ausübbar am 23.02.2029) und 4.186.049 Aktien zu $1,25 (ausübbar am 29.07.2030). Einige Warrants enthalten eine Ausübungsbeschränkung von 9,99% des Eigentums.